WCN26-9046 PEGCETACOPLAN FOR 52 WEEKS MAINTAINS PROTEINURIA REDUCTION AND EGFR STABILIZATION FOR PEDIATRIC PATIENTS: PHASE 3 VALIANT SUBGROUP ANALYSIS

Read full text Summarise with VIRAT
Authors: Larry A. Greenbaum, Carla Nester, Gema Ariceta, Bradley P. Dixon, Yael Borovitz, Christoph P. B. Licht, Antonio Mastrangelo, Nabil Ziad Melhem, Naoya Fujita, Nicole C. A. J. van de Kar, Dean Wallace, Anwesha Mukherjee
+3 more Elena Surova, Johan Szamosi, Marina Vivarelli
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

C3 glomerulopathy (C3G) and primary immune-complex mediated membranoproliferative glomerulonephritis (IC-MPGN) are often diagnosed in childhood. In the 26-week randomized controlled period (RCP) of VALIANT (phase 3; NCT05067127), pegcetacoplan (C3/C3b inhibitor) for C3G and primary IC-MPGN led to significant proteinuria reduction vs placebo and estimated glomerular filtration rate (eGFR) stabilization for adolescents (12–17 years) and the overall population. In the following 26-week open-label period (OLP), all patients received pegcetacoplan.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Complement system in diseases Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106327–106327
Publication date
25 March 2026
Language
EN